Venus Remedies secures Ukrainian GMP renewal

Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards

Pfizer inks $1.25 billion cancer antibody licensing deal with China's 3SBio

3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion

Venus Remedies joins United Nations Global Compact

This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery

Briefs: Dr. Reddy's Laboratories, Relonchem, Shilpa Pharma Lifesciences and Shanmuga Hospital

Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA

Sun Pharma gets FDA approval for new device to treat skin disease

Lupin receives USFDA approval for Rivaroxaban Tablets

Alembic Pharmaceuticals receives USFDA final approval for Rivaroxaban Tablets USP

Sanofi India posts 27% growth in operating profits in Q1 2025

Standalone profit from operations for the quarter were Rs. 162 crores

Bayer confirms 2025 targets after solid start to the year

EBITDA before special items decreases to €4.08 billion (7.4%)

Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr

PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%